ASTH — Astrana Health Inc.
Is ASTH overbought or oversold? Here is the current MarketMoodz read.
Astrana Health Inc. (ASTH) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $31.99. The rating moved from Strong Oversold to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$31.99
- Last changeMoved from Strong Oversold to Oversold on November 13, 2026
- SectorHealthcare
- IndustryMedical Care Facilities
See all oversold Healthcare stocks →
AI analysis
Astrana Health Inc. (ASTH) presents limited publicly available data and modest market attention, producing an unclear fundamental picture. The broader healthcare backdrop is mixed — defensive large‑cap pharma flows are supportive while proposed CMS Medicare integrity measures raise near‑term regulatory and reimbursement uncertainty. Potential upside depends on successful execution into specialty services or profitable participation in payer/provider channels, but information gaps, low liquidity, and competitive pressure increase the probability of volatile moves on company‑specific news. Monitor upcoming filings, revenue disclosures, and any announcements related to Medicare exposure or specialty service contracts to reassess trajectory.
Key factors
- Limited public financial disclosure and no EDGAR filing comparison available, making fundamental assessment incomplete
- General healthcare market backdrop is mixed: defensive large‑cap pharma flows are supporting parts of the sector while regulatory scrutiny on Medicare programs increases uncertainty
- Medicare Advantage regulatory proposals increase near‑term reimbursement and compliance risk for firms exposed to MA economics or related services
- Sector rotation and muted volatility suggest consolidation rather than strong directional moves, limiting near‑term catalysts from broader market action
- Potential strategic opportunities if the company participates in specialty pharmacy, infusion, or biopharma services given distributor shifts toward specialty channels
- Liquidity and investor attention appear limited based on lack of social/research coverage, raising the cost of capital and amplification of moves on news
Risks
- Heightened regulatory and compliance risk from CMS proposals could pressure revenue or margins if the business is tied to Medicare Advantage flows
- Sparse public reporting and limited analyst coverage increase information asymmetry and make downside surprise risk higher
- Small‑cap / low liquidity dynamics could lead to outsized price moves on modest news or insider activity
- Competitive pressures from larger, better‑capitalized healthcare and services players could constrain growth or margin expansion
- Reimbursement changes, clawbacks, or RADV adjustments could materially affect near‑term cash flow if exposure to MA is meaningful
- Execution risk on any strategic initiatives (partnerships, expansion into specialty services) given constrained resources
See today's live rating, score and targets
Members see the live hourly rating for ASTH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.